Skip to main content

CombiMatrix Finalizes Split with Acacia Research, Begins Trading on Nasdaq

NEW YORK (GenomeWeb News) - CombiMatrix has completed its split from former parent company Acacia Research through a share swap and this morning began trading on the Nasdaq Capital Market, the companies said today in separate statements.
The US Securities and Exchange Commission approved the break-up plan in June.
CombiMatrix initially filed its plan to split from Acacia in December 2006. CEO Amit Kumar said at the time that the split would enable each company to forge independent business plans, and would afford CombiMatrix the freedom to “invent ourselves with a focus on molecular diagnostics and personalized medicine.”
The split took place through a share trade, under which every 10 shares of Acacia Research-CombiMatrix common stock was traded for one share of CombiMatrix common stock.
CombiMatrix began trading today under the symbol “CBMXD,” but will shift to “CBMX” after 20 days, at which time Acacia will begin trading under the symbol “ACTG.”
Shares opened today at $5.96 a share, and were down more than 7 percent, to $5.55 a share, in mid-afternoon trading.
The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.